Patient-reported outcomes following pembrolizumab or placebo plus pemetrexed and platinum in patients with previously untreated, metastatic, non-squamous non-small-cell lung cancer (KEYNOTE-189): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind ◽

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study

The Lancet Oncology ◽

10.1016/s1470-2045(19)30519-4 ◽

2019 ◽

Vol 20 (12) ◽

pp. 1670-1680 ◽

Cited By ~ 22

Author(s):

Rina Hui ◽

Mustafa Özgüroğlu ◽

Augusto Villegas ◽

Davey Daniel ◽

David Vicente ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Stage Iii ◽

Small Cell Lung ◽

Phase 3 ◽

Patient Reported ◽

Randomised Controlled

417O Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs)

Annals of Oncology ◽

10.1093/annonc/mdv532.01 ◽

2015 ◽

Vol 26 ◽

pp. ix125 ◽

Cited By ~ 9

Author(s):

L. Horn ◽

J. Brahmer ◽

M. Reck ◽

H. Borghaei ◽

D.R. Spigel ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Randomized Trial ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Patient Reported ◽

Subgroup Analyses

Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer

Current Medical Research and Opinion ◽

10.1080/03007995.2020.1808781 ◽

2020 ◽

Vol 36 (10) ◽

pp. 1667-1675 ◽

Cited By ~ 2

Author(s):

Kiyotaka Yoh ◽

Shinji Atagi ◽

Martin Reck ◽

Edward B. Garon ◽

Santiago Ponce Aix ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Phase 3 ◽

Patient Reported ◽

Egfr Mutated

Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours

ESMO Open ◽

10.1016/j.esmoop.2021.100113 ◽

2021 ◽

Vol 6 (3) ◽

pp. 100113

Author(s):

L. Paz-Ares ◽

F. Barlesi ◽

S. Siena ◽

M.-J. Ahn ◽

A. Drilon ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Phase Ii ◽

Cell Lung Cancer ◽

Small Cell ◽

Solid Tumours ◽

Small Cell Lung ◽

138PD_PR Patient-reported outcomes (PROs) in ALEX: A phase III study of alectinib (ALEC) vs crizotinib (CRIZ) in non-small-cell lung cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1016/s1556-0864(18)30412-x ◽

2018 ◽

Vol 13 (4) ◽

pp. S80-S81 ◽

Cited By ~ 1

Author(s):

M. Perol ◽

S. Peters ◽

N. Pavlakis ◽

E. Levchenko ◽

M. Platania ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

Patient Reported ◽

Phase Iii Study

HSR21-067: What Patient-Reported Outcomes Are Being Used in Non-small Cell Lung Cancer? A Targeted Literature Review of Randomized Clinical Trials and Regulatory Labeling

Journal of the National Comprehensive Cancer Network ◽

10.6004/jnccn.2020.7726 ◽

2021 ◽

Vol 19 (3.5) ◽

pp. HSR21-067

Author(s):

Kajal Patel ◽

Soham Shukla ◽

Jennifer Hanlon ◽

Kelly Bell ◽

Laurie Eliason ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Trials ◽

Literature Review ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Randomized Clinical Trials ◽

Small Cell ◽

Small Cell Lung ◽

Early Postoperative Patient-Reported Outcomes After Thoracoscopic Segmentectomy Versus Lobectomy for Small-Sized Peripheral Non-small-cell Lung Cancer

Annals of Surgical Oncology ◽

10.1245/s10434-021-10946-7 ◽

2021 ◽

Author(s):

Wei Dai ◽

Shuai Chang ◽

Cecilia Pompili ◽

Bin Qiu ◽

Xing Wei ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Postoperative Patient ◽

Are the data on quality of life and patient reported outcomes from clinical trials of metastatic non-small-cell lung cancer important?

World Journal of Clinical Oncology ◽

10.5306/wjco.v4.i4.82 ◽

2013 ◽

Vol 4 (4) ◽

pp. 82 ◽

Cited By ~ 8

Author(s):

Vera Hirsh

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Clinical Trials ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Patient-Reported Outcomes of Chemotherapy Involving Non-Small Cell Lung Cancer: Evaluation by Questionnaires of Quality of Life Regarding Anti-Aging and Anti-Cancer Drugs

Advances in Lung Cancer ◽

10.4236/alc.2017.62002 ◽

2017 ◽

Vol 06 (02) ◽

pp. 13-35

Author(s):

Takanori Ayabe ◽

Masaki Tomita ◽

Takashi Asada ◽

Kazuyo Tsuchiya ◽

Manabu Nemoto ◽

...

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Patient Reported ◽

Anti Cancer

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

The Lancet Oncology ◽

10.1016/s1470-2045(13)70510-2 ◽

2014 ◽

Vol 15 (1) ◽

pp. 59-68 ◽

Cited By ~ 259

Author(s):

Charles Butts ◽

Mark A Socinski ◽

Paul L Mitchell ◽

Nick Thatcher ◽

Libor Havel ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Stage Iii ◽

Small Cell Lung ◽

Phase 3 ◽

Double Blind